204 related articles for article (PubMed ID: 24058655)
1. Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.
Gunda DW; Kasang C; Kidenya BR; Kabangila R; Mshana SE; Kidola J; Kalluvya SE; Kongola GW; Klinker H
PLoS One; 2013; 8(9):e75118. PubMed ID: 24058655
[TBL] [Abstract][Full Text] [Related]
2. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
Cressey TR; Green H; Khoo S; Treluyer JM; Compagnucci A; Saidi Y; Lallemant M; Gibb DM; Burger DM;
Clin Infect Dis; 2008 May; 46(10):1601-8. PubMed ID: 18419497
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
Stöhr W; Back D; Dunn D; Sabin C; Winston A; Gilson R; Pillay D; Hill T; Ainsworth J; Pozniak A; Leen C; Bansi L; Fisher M; Orkin C; Anderson J; Johnson M; Easterbrook P; Gibbons S; Khoo S; ;
Antivir Ther; 2008; 13(5):675-85. PubMed ID: 18771051
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
Wyen C; Hendra H; Vogel M; Hoffmann C; Knechten H; Brockmeyer NH; Bogner JR; Rockstroh J; Esser S; Jaeger H; Harrer T; Mauss S; van Lunzen J; Skoetz N; Jetter A; Groneuer C; Fätkenheuer G; Khoo SH; Egan D; Back DJ; Owen A;
J Antimicrob Chemother; 2008 Apr; 61(4):914-8. PubMed ID: 18281305
[TBL] [Abstract][Full Text] [Related]
6. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.
Lowenthal ED; Ellenberg JH; Machine E; Sagdeo A; Boiditswe S; Steenhoff AP; Rutstein R; Anabwani G; Gross R
JAMA; 2013 May; 309(17):1803-9. PubMed ID: 23632724
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.
Xu L; Peng W; Song X; Li Y; Han Y; Zhu T; Fu Q; Du X; Cao W; Li T
BMC Infect Dis; 2021 Jan; 21(1):112. PubMed ID: 33485301
[TBL] [Abstract][Full Text] [Related]
8. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
[TBL] [Abstract][Full Text] [Related]
9. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
[TBL] [Abstract][Full Text] [Related]
10. Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
Mazanderani AH; Murray TY; Sherman GG; Snyman T; George J; Avenant T; Goga AE; Pepper MS; du Plessis N
J Int AIDS Soc; 2019 Jun; 22(6):e25284. PubMed ID: 31215757
[TBL] [Abstract][Full Text] [Related]
11. Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi.
Calcagno A; Motta I; Milia MG; Rostagno R; Simiele M; Libanore V; Fontana S; D'Avolio A; Ghisetti V; Di Perri G; Bonora S
Br J Clin Pharmacol; 2015 May; 79(5):801-8. PubMed ID: 25377591
[TBL] [Abstract][Full Text] [Related]
12. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
[TBL] [Abstract][Full Text] [Related]
13. [Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia].
Martorell M; López RM; Ribera E; Ruiz I; Tural C; Puig L; Monterde J
Enferm Infecc Microbiol Clin; 2005; 23(6):349-52. PubMed ID: 15970167
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.
Bednasz CJ; Venuto CS; Ma Q; Daar ES; Sax PE; Fischl MA; Collier AC; Smith KY; Tierney C; Yang Y; Wilding GE; Morse GD
Ther Drug Monit; 2017 Dec; 39(6):596-603. PubMed ID: 29135907
[TBL] [Abstract][Full Text] [Related]
15. Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
Dahri K; Ensom MH
Clin Pharmacokinet; 2007; 46(2):109-32. PubMed ID: 17253884
[TBL] [Abstract][Full Text] [Related]
16. Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania.
Sungi SS; Ngaimisi E; Ulenga N; Sasi P; Mugusi S
BMC Pharmacol Toxicol; 2018 Oct; 19(1):66. PubMed ID: 30352627
[TBL] [Abstract][Full Text] [Related]
17. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
Chen J; Sun J; Ma Q; Yao Y; Wang Z; Zhang L; Li L; Sun F; Lu H
Ther Drug Monit; 2010 Oct; 32(5):573-8. PubMed ID: 20625352
[TBL] [Abstract][Full Text] [Related]
18. Detecting virological failure in HIV-infected Tanzanian children.
Mgelea EM; Kisenge R; Aboud S
S Afr Med J; 2014 Jun; 104(10):696-9. PubMed ID: 25363057
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and durability of nevirapine in antiretroviral drug näive patients.
Lange JM
J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S40-52. PubMed ID: 14562857
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.
Ma Q; Zingman BS; Luque AE; Fischl MA; Gripshover BM; Venuto CS; DiFrancesco R; Forrest A; Morse GD
Ther Drug Monit; 2011 Jun; 33(3):309-14. PubMed ID: 21544014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
